News & Podcast
Stay up to date with the latest stories, deep-dives and interviews from the Munich startup ecosystem. From funding deals to founder portraits and tech trends.
Smartbax secures €6.3 million for antibiotics with new mechanism of action
Million-euro funding for Munich biotech startup: Smartbax has expanded its Pre-Series A financing round to a total of €6.3 million. Find out here why this research is important for all of us and exactly what the money will be used for.
Smartbax: New antibiotics against superbugs
Smartbax develops innovative antibiotics against multidrug-resistant bacteria with a completely new mechanism of action: instead of blocking processes, they cause pathogens to self-destruct. Emerging from research at TU München, the startup is working on clinical trials while fighting against the resistance crisis and market hurdles.
Smartbax raises 4.7 million euros
Munich biotech startup Smartbax secures 4.7 million euros in a Pre-Series A round. With the capital, the team aims to further develop its next-generation antibiotics against multidrug-resistant bacteria.